Clinical trial
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in…
NCT00228176 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00228176 |
|---|---|
| Title | Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant |
| Official title | Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors |
| Acronym | AUDITOR |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X |
| Intervention type | Drug |
| Interventions | Rimonabant, Placebo (for Rimonabant) |
| Enrollment | 661 |
| Start date | Aug 1, 2005 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Sep 28, 2005 |
| Last update posted | May 20, 2016 |
| Countries | Canada, France, Netherlands, Spain, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: